BioCentury
ARTICLE | Financial News

Abpro planning $69M NASDAQ listing

April 13, 2018 5:21 PM UTC

Antibody company Abpro Corp. (Woburn, Mass.) filed on April 12 to raise up to $69 million in an IPO on NASDAQ underwritten by UBS, Wells Fargo, Nomura and Oppenheimer.

Abpro's two lead programs, ABP-100 and ABP-201, are designed to bind to two different binding sites on each of two targets using Abpro's TetraBi tetravalent antibody format. The company hopes to begin clinical testing of ABP-100 in 1H19 and ABP-201 in 2H19...